

Staphylococcus aureus - NRS402

Other designations (HIP12864)

Demographic Information:			
Country/State:	United States / Oklahoma	Date of Isolation:	10/15/2003
Patient Age:	78 Year(s)	Gender:	Male
Patient Location:	N/A	Patient Service:	N/A
Culture Source:			
Literature Citation:	N/A		
Donor Reported MIC Results (ug/ml)	Vancomycin = 8	Teicoplanin = 16	
Comment:	VISA from Oklahoma		
Repositories:	Glycopeptide Intermediate Staphylococci		

NARSA Antimicrobial Susceptibility Data for Glycopeptides

Drug	Broth Microdilution		^a Conventional Etest 0.5 McFarland Std		^b Modified Etest 2 McFarland Std		^c BHI Agar Screen	Disk Diffusion	
	$\mu\text{g/mL}$ MIC ug/ml	CLSI Interprtn	MIC $\mu\text{g/ml}$	CLSI Interprtn	MIC $\mu\text{g/ml}$	CLSI Interprtn		Zone di am. (mm)	CLSI Interprtn
Vancomycin:			= 8	I	= 48	R	CG(24)	17	S
Teicoplanin:			= 24	I	= 96	R		13	I

S = Susceptible; R = Resistant; NS = Not Susceptible; I =Intermediate; N/A = Not Available P= Pending results

NARSA Antimicrobial Profile for Other Antimicrobial Agents			Molecular Characterization Data	
Drug	$\mu\text{g/mL}$ MIC ug/ml	CLSI Interprtn	PCR	Result
Ciprofloxacin	> 16	R	<i>vanA</i>	NEGATIVE
Clindamycin	> 4	R	<i>vanB</i>	NEGATIVE
Daptomycin	= 4	N/A	<i>vanC1</i>	NEGATIVE
Erythromycin	> 8	R	<i>vanC2</i>	NEGATIVE
Gentamicin	= 0.25	S	<i>vanD</i>	NEGATIVE
Linezolid	= 0.5	S	<i>vanE</i>	NEGATIVE
Oxacillin	> 16	R	<i>mecA</i>	POSITIVE
Penicillin	> 2	R		
Quinupristin/dalfopristin	= 0.25	S		
Trimeth/sulfa	<= 0.25/4.75	S		

Genotype Data	
Genotype	Result
eGenomic <i>spa</i> type	2
eGenomic <i>spa</i> repeats	TJMBMDMGMK
Ridom <i>spa</i> type	t002
SCC <i>mec</i> type	II
Clonal Complex (CC)	5
Sequence Type (ST)	5
Genotype Data file	